neutropenia

Review of the ASCO and IDSA clinical practice guidelines on antimicrobial prophylaxis for adult patients with cancer-related immunosupression

Clinical Microbiology and Antimicrobial Chemotherapy. 2019; 21(1):4-17

10.36488/cmac.2019.1.4-17

Patients undergoing cytotoxic chemotherapy and hematopoietic stem-cell transplantation are at risk for infection. The risk of infections increases with the depth and duration of neutropenia, with the greatest risk occurring in patients who experience …

Empirical, Pre-emptive and Prophylactic Therapy of Invasive Mycoses: Current State of the Problem

Clinical Microbiology and Antimicrobial Chemotherapy. 2009; 11(4):286-304

Invasive mycoses in patients with severe diseases – ICU patients, patients with hematological malignancies and after solid organ transplantations represent a significant target for the use of prophylactic, empirical and pre-emptive antifungal …

Practice Guidelines for the Antimicrobial Therapy in Neutropenic Patients with Cancer (According to the Guidelines of Infections Diseases Society of America)

Clinical Microbiology and Antimicrobial Chemotherapy. 2003; 5(1):47-73

Febrile neutropenia is becoming significant problem in Russian medical institutions. Changes in spectrum of causative pathogens, increase of the number of neutropenic patients and emergence of antimicrobial resistance – all the above factors require …

Efficacy of Cefepime Monotherapy and The Combination of Ceftazidime with an Aminoglycoside in The Treatment of Infections in Oncology Patients with Severe Neutropenia

Clinical Microbiology and Antimicrobial Chemotherapy. 2001; 3(4):339-347

The combination of ceftazidime with an aminoglycoside is a commonly used standard for empiric therapy of febrile neutropenia. A lot of attention is paid to the development of effective monotherapy for the treatment of this condition. One of the most …